Patterns of patient enrollment in randomized controlled trials

被引:67
作者
Haidich, AB
Ioannidis, JPA [1 ]
机构
[1] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece
[2] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA
关键词
HIV; modeling; patient enrollment; randomized controlled trials; sample size; study design;
D O I
10.1016/S0895-4356(01)00353-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
We aimed to describe enrollment patterns in a large cohort of randomized controlled trials (RCTs) and evaluate whether early recruitment predicts the ability of RCTs to reach their target enrollment. We considered all 77 efficacy RCTs initiated by the AIDS Clinical Trials Group between 1986 and 1996 (28,992 patients enrolled until November 1999). Thirteen RCTs (17%) failed to reach half their target recruitment. Enrollment trajectories showed that the initial rate of accrual determined the subsequent rates of enrollment. The target sample size was attained by 7/8, 11/14, 15/35 and 4/20 of trials with very rapid, rapid, moderate and slow enrollment during the first 3 months, respectively (P < 0.001). Enrollment during the first month or two strongly correlated with subsequent accrual (P < 0.001) The patient pool, the eligibility criteria, the attractiveness of a trial and adequacy of the network of clinical sites may influence RCT enrollment. Early enrollment offers strong evidence on the feasibility of a trial and is indicative of its future pace of recruitment. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:877 / 883
页数:7
相关论文
共 20 条
[1]  
[Anonymous], 2013, Clinical trials: a practical approach
[2]   A RANDOMIZED TRIAL OF 3 ANTIPNEUMOCYSTIS AGENTS IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
BOZZETTE, SA ;
FINKELSTEIN, DM ;
SPECTOR, SA ;
FRAME, P ;
POWDERLY, WG ;
HE, WL ;
PHILLIPS, L ;
CRAVEN, D ;
VANDERHORST, C ;
FEINBERG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (11) :693-699
[3]  
Chalmers TC, 1996, STAT MED, V15, P1263, DOI 10.1002/(SICI)1097-0258(19960630)15:12<1263::AID-SIM305>3.0.CO
[4]  
2-K
[5]   REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT [J].
CONNOR, EM ;
SPERLING, RS ;
GELBER, R ;
KISELEV, P ;
SCOTT, G ;
OSULLIVAN, MJ ;
VANDYKE, R ;
BEY, M ;
SHEARER, W ;
JACOBSON, RL ;
JIMENEZ, E ;
ONEILL, E ;
BAZIN, B ;
DELFRAISSY, JF ;
CULNANE, M ;
COOMBS, R ;
ELKINS, M ;
MOYE, J ;
STRATTON, P ;
BALSLEY, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) :1173-1180
[6]   ARE CLINICAL-TRIALS A COST-EFFECTIVE INVESTMENT [J].
DETSKY, AS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 262 (13) :1795-1800
[7]   USING ECONOMIC-ANALYSIS TO DETERMINE THE RESOURCE CONSEQUENCES OF CHOICES MADE IN PLANNING CLINICAL-TRIALS [J].
DETSKY, AS .
JOURNAL OF CHRONIC DISEASES, 1985, 38 (09) :753-765
[8]   USING COST-EFFECTIVENESS ANALYSIS TO IMPROVE THE EFFICIENCY OF ALLOCATING FUNDS TO CLINICAL-TRIALS [J].
DETSKY, AS .
STATISTICS IN MEDICINE, 1990, 9 (1-2) :173-184
[9]   Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials [J].
Ioannidis, JPA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (04) :281-286
[10]  
Ioannidis JPA, 1998, AM J EPIDEMIOL, V148, P1117